10-Q: Goldenwell Biotech Reports Q3 2024 Results with Ongoing Losses and Focus on Capital Raising

Goldenwell Biotech's Q3 2024 report reveals continued losses and minimal revenue, highlighting the company's reliance on future capital raising for operational sustainability.

Summary

• Goldenwell Biotech reported its financial results for the third quarter of 2024, showing a net loss of $23,065 for the quarter and $103,962 for the nine-month period.
• The company's revenue was minimal, with $0 in sales for the quarter and only $297 for the nine-month period.
• Operating expenses were $23,065 for the quarter and $104,111 for the nine-month period.
• The company's cash balance stood at $4,755 as of September 30, 2024, with a working capital deficit of $19,239.
• Goldenwell Biotech has an accumulated net loss of $1,331,643 since its inception.
• The company's ability to continue as a going concern is dependent on raising capital to fund its business plan.
• The company has related-party loans totaling $95,558 and unrelated party loans of $119,250.
• The company plans to raise additional funds through debt or equity offerings, but there is no guarantee of success.

Sentiment

Score: 3

Explanation: The document indicates a weak financial position with minimal revenue, significant losses, and a reliance on future capital raising. The company's ability to continue as a going concern is uncertain, leading to a negative sentiment.

Positives

• The company has identified a plan to increase sales of its products.
• The company believes it can satisfy its cash requirements through the fiscal year end of December 31, 2024, from its cash of $4,755 as of September 30, 2024.

Negatives

• The company has minimal revenue, with $0 in sales for the quarter and only $297 for the nine-month period.
• The company has incurred significant net losses, with $23,065 for the quarter and $103,962 for the nine-month period.
• The company has a working capital deficit of $19,239.
• The company's cash balance is low at $4,755.
• The company has an accumulated net loss of $1,331,643 since its inception.
• The company's ability to continue as a going concern is dependent on raising capital.
• There is no guarantee that the company will be able to raise the necessary capital.

Risks

• The company's ability to continue as a going concern is dependent on raising capital.
• There is no guarantee that the company will be able to raise the necessary capital through debt or equity offerings.
• The company has minimal revenue and significant losses.
• The company has a working capital deficit.
• The company needs approximately $5,000,000 to complete its manufacturing facilities.
• Existing shareholders will experience dilution if the company is successful in completing an equity financing.
• The company's business will fail in the absence of sufficient financing.

Future Outlook

The company plans to increase sales of its products and raise additional funds through debt or equity offerings. The company estimates it needs approximately $5,000,000 to complete its manufacturing facilities and that it would take approximately one year to complete such activities.

Management Comments

• The company's ability to continue as a going concern is dependent on raising capital to fund our business plan and ultimately to attain profitable operations.
• We believe we can satisfy our cash requirements through the fiscal year end of December 31, 2024, from our cash of $4,755 as of September 30, 2024.
• We estimate that we need approximately $5,000,000 to complete such activities and that it would take approximately one year to complete such activities.

Industry Context

The company is operating in the nutraceutical and dietary supplements industry, which is competitive and requires significant capital investment for manufacturing and sales. The company's current financial situation is not uncommon for early-stage companies in this sector, but the lack of revenue and significant losses highlight the challenges it faces.

Comparison to Industry Standards

• Many early-stage biotech and nutraceutical companies experience losses in their initial phases as they invest in research, development, and infrastructure.
• Compared to companies like Amyris or Ginko Bioworks, which have raised significant capital, Goldenwell Biotech's current financial position is precarious.
• The lack of revenue and reliance on related-party loans is a concern compared to industry standards where companies often have some level of sales or external funding.
• The company's need for $5,000,000 to complete manufacturing facilities is a significant hurdle, and the timeline of one year is ambitious compared to similar projects in the industry.

Related Party Transactions

• The company purchased inventory of $103,125 from Australian Trefoil Heath Technology, which is owned by Li, Yang, the Treasurer of the Company.
• The company has borrowed a total of $95,599 from Shuang Liu, the Chief Executive Officer of the Company.

Stakeholder Impact

• Shareholders face the risk of dilution if the company raises capital through equity offerings.
• Employees' job security is uncertain due to the company's financial instability.
• Customers may be impacted by the company's ability to deliver products due to its financial challenges.
• Suppliers and creditors face the risk of non-payment if the company fails to secure additional funding.

Next Steps

• The company plans to increase the sales of its products.
• The company plans to raise additional funds through debt or equity offerings.
• The company needs to construct manufacturing facilities, including locating a site, installing a workshop, and setting up equipment.
• The company needs to train its workforce.

Key Dates

Keywords

Biotech, Financial Results, Quarterly Report, Capital Raising, Net Loss, Revenue, Operating Expenses, Going Concern, Debt Financing, Equity Financing